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Abstract
There is rapidly mounting evidence that intracellular proteases in bacteria are compelling targets 
for antibacterial drugs. Multiple reports suggest that the human pathogen Mycobacterium 
tuberculosis and other actinobacteria may be particularly sensitive to small molecules that perturb 
the activities of self-compartmentalized peptidases, which catalyze intracellular protein turnover 
as components of ATP-dependent proteolytic machines. Here, we report chemical syntheses and 
evaluations of structurally diverse β-lactones, which have a privileged structure for selective, 
suicide inhibition of the self-compartmentalized ClpP peptidase. β-lactones with certain 
substituents on the α- and β-carbons were found to be toxic to M. tuberculosis. Using an affinity-
labeled analog of a bioactive β-lactone in a series of chemical proteomic experiments, we 
selectively captured the ClpP1P2 peptidase from live cultures of two different actinobacteria that 
are related to M. tuberculosis. Importantly, we found that the growth inhibitory β-lactones also 
inactivate the M. tuberculosis ClpP1P2 peptidase in vitro via formation of a covalent adduct at the 
ClpP2 catalytic serine. Given the potent antibacterial activity of these compounds and their 
medicinal potential, we sought to identify innate mechanisms of resistance. Using a genome 
mining strategy, we identified a genetic determinant of β-lactone resistance in Streptomyces 
coelicolor, a non-pathogenic relative of M. tuberculosis. Collectively, these findings validate the 
potential of ClpP inhibition as a strategy in antibacterial drug development and define a 
mechanism by which bacteria could resist the toxic effects of ClpP inhibitors.
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The rising number of deaths resulting from infections with multi-drug resistant pathogens is 
a public health crisis (1). The drug-resistance problem is evident in the case of 
Mycobacterium tuberculosis, the causative agent of tuberculosis (2). Efforts are underway 
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for the discovery and development of new antibacterial agents that are effective against 
multi-drug resistant strains of M. tuberculosis (1,2,5). Drug development has been aided by 
a renewed focus on the physiology of this pathogen (2,7,9–12). Through screens for 
conditionally or absolutely essential genes, it has been established that enzymes associated 
with intracellular protein turnover are particularly important in mycobacterial physiology. 
For example, genes encoding the ClpP peptidase and its AAA+ partners, ClpX and ClpC1, 
are absolutely essential for the viability of the bacterium (7, 10). The ClpP peptidase is a 
self-compartmentalized barrel-shaped tetradecamer, composed of two heptameric rings that 
enclose a degradation chamber (7,8,18). By itself, ClpP degrades small peptides, but its 
small axial pores exclude large peptides and folded proteins from the proteolytic chamber. 
The AAA+ partners of ClpP are ring hexamers that recognize, unfold, and translocate 
substrates into the ClpP chamber in ATP-dependent reactions (8,13,14). Mycobacterial ClpP 
plays critical roles in protein turnover, but is distinct in many ways from its orthologs in 
other bacteria. For instance, ClpP is essential in mycobacteria and in other actinobacteria, 
but is only required for virulence and stress tolerance in other pathogenic bacteria (12,15–
17). Another unusual feature of mycobacteria and other actinobacteria is that they often 
harbor two clpP genes (clpP1 and clpP2), typically in a dicistronic operon (7,12,18); 
whereas most bacteria have a single clpP gene. Biochemical studies suggest that 
mycobacterial ClpP1 and ClpP2 form distinct homo-heptameric rings, which assemble into 
an active ClpP17•ClpP27 heterotetradecameric complex (7, 18), which we will call ClpP1P2.
Because the genes encoding ClpP1 and ClpP2 are essential for the viability of M. 
tuberculosis, there have been efforts to discover and develop small molecules that perturb 
the activities of these enzymes (12,19–29). Parish and co-workers reported that 
acyldepsipeptides (ADEPs), which dysregulate ClpP function by opening the axial pore and 
causing unregulated protein degradation, are toxic to M. tuberculosis (10,29). Although 
ADEPs are attractive drug leads, they must be used in conjunction with efflux-pump 
inhibitors to realize low MICs in M. tuberculosis (10,29). Cyclomarin A1, a molecule that 
activates ClpP by binding to its AAA+ ClpC1 partner, has also been reported to kill M. 
tuberculosis (27,29). These drug leads validate the strategy of killing M. tuberculosis via 
small molecule-mediated activation of ClpP1P2 (10,27,29).
An appealing but unvalidated strategy for killing M. tuberculosis is small molecule-
mediated inhibition of ClpP1P2. Insights into how the mycobacterial ClpP might be 
inhibited can be gleaned from molecules that inhibit its counterparts in other bacteria. For 
example, the Keiler group identified cyclic peptides that inhibit ClpXP in Caulobacter 
crescentus by an unknown mechanism (28). Consistent with the requirement of the clpP and 
clpX genes for cell-cycle progression in C. crescentus, these inhibitory peptides are toxic to 
this bacterium. Analogously, Sieber and co-workers have reported that ClpP-dependent 
production of virulence factors in Staphylococcus aureus and Listeria monocytogenes is 
suppressed by β-lactones that selectively inhibit ClpP (20–23,25). These molecules are 
“suicide inhibitors” because the active-site serine of ClpP attacks the electrophilic carbonyl 
of the β-lactone ring, resulting in the formation of an inactive O-acyl-enzyme product (25). 
Here, we report syntheses of novel β-lactones and show that some of them are toxic to 
Mycobacterium smegmatis and M. tuberculosis. Chemical proteomic experiments indicate 
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that the β-lactones react with actinobacterial ClpP in vivo. We present evidence that these 
compounds inhibit the peptidase activity of M. tuberculosis ClpP1P2 in vitro by modifying 
the active-site serine of ClpP2. Furthermore, we successfully used a genome mining strategy 
to identify an innate mechanism of β-lactone resistance in a Streptomyces coelicolor, a non-
pathogenic relative of mycobacteria (30). Collectively, these results have important 
implications for the development of ClpP inhibitors as anti-tuberculosis drugs.
RESULTS AND DISCUSSION
β-lactones are toxic to Mycobacteria
Based on the essentiality of the clpP locus in M. tuberculosis, we hypothesized that the 
bacterium would be susceptible to molecules possessing the β-lactone core structure that is 
common to suicide inhibitors of ClpP peptidases in a variety of bacterial species. Because 
there was insufficient information to predict which structural features an inhibitor of 
mycobacterial ClpP might possess, we used methodology developed by either Danheiser or 
Romo (31,32) to synthesize compounds with a common β-lactone core but with structurally 
disparate substituents attached to the α- and β-carbons, including hydrogen atoms, straight 
and branched aliphatic groups, or an aromatic moiety. Our collection also included β-
lactones with two substituents at the β-carbon or with fused rings. In total, we synthesized 
12 different β-lactones (compounds 2–13; Fig. 1), typically in moderate to poor yields 
because of chemical instability and/or difficulties in separating the desired products from 
starting materials.
For biological testing, we included two commercially available compounds (β-lactones 1 
and 14; Fig. 1) together with our newly synthesized β-lactones. Of these 14 molecules, four 
prevented growth of M. smegmatis MC2155 (Table 1), a non-pathogenic surrogate of the 
human pathogen M. tuberculosis. Three of these inhibitory compounds were trans-
disubstituted β-lactones with unbranched alkyl substituents on both the α- and β-carbons (β-
lactones 2–4; Fig. 1). For these molecules, there was a positive correlation between the 
length of the alkyl group on the α-carbon and antibacterial activity. However, the most 
potent compound (β-lactone 7; Fig. 1; MIC = 10 μg/mL) had an aromatic benzyl substituent 
on the α-carbon and an unbranched n-propyl group on the β-carbon. Compounds with only 
one substituent, with branching or disubstitution at the β-carbon, or with the β-lactone fused 
to another ring (β-lactones 1, 5, 6, 8–14; Fig. 1) did not prevent growth of M. smegmatis at 
the concentrations tested. Clearly, the simple β-lactone core structure is not sufficient for 
inhibition of M. smegmatis growth, and the chemical identity of groups attached to the α- 
and β-carbons dictates antibacterial activity against M. smegmatis and potentially other 
actinobacteria.
The two most active compounds (β-lactone 4 and 7) from the activity assays with M. 
smegmatis were subsequently tested for their ability to inhibit the growth of the human 
pathogen, M. tuberculosis H37Rv. Strikingly, both molecules also inhibited growth of M. 
tuberculosis H37Rv (Table 1), with β-lactone 7 being the most active against M. smegmatis 
and M. tuberculosis. These findings are noteworthy because β-lactones were not previously 
recognized as a family of privileged structures that inhibit the growth of M. tuberculosis.
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β-lactones target actinobacterial ClpP1P2 in vivo
Disubstituted β-lactones are thought to be privileged structures for the selective inhibition of 
the ClpP peptidase. We designed a chemical proteomic experiment in which we could 
capture and analyze cytoplasmic proteins with which the β-lactones had reacted in vivo. 
Specifically, we synthesized a bioactive analog of β-lactone 7 (the most potent compound) 
that has a n-pentynl substituent on the β-carbon in place of the parent's n-propyl substituent. 
The alkyne moiety was purposefully included because it could be used as a reactant in a 
“click” reaction for capture of proteins with which the β-lactone formed adducts. For the 
experiments, shaken liquid cultures of both S. coelicolor and M. smegmatis were treated 
with the alkynyl β-lactone. These organisms were chosen because they represent two 
different genera of actinobacteria that require a heterotetradecameric ClpP for viability 
(7,43,44). After mild cell lyses, the lysates were sequentially treated with azido-biotin, a 
copper (II) catalyst for the click reaction, and an avidin-functionalized agarose resin. In 
parallel, control experiments were performed in which the cell lysates were not treated with 
the Cu (II)-catalyst or with azido-biotin or were treated only with the avidin-functionalized 
agarose resin. In all cases, the protein-enriched resins were treated with trypsin and the 
resulting peptides were identified by a combination of peptide mass-fingerprinting and 
bioinformatic analysis via MASCOT software. After the elimination of all proteins that were 
identified in the negative control experiments, we identified 8 and 13 proteins that were 
captured from the cell lysates of S. coelicolor and M. smegmatis, respectively (Tables 2, S4 
and S5). Presuming that growth inhibitory β-lactones would have the same targets in both S. 
coelicolor and M. smegmatis, we generated a list of the proteins that were captured from the 
lysates of both species via the click reaction. We were gratified to find ClpP1 and ClpP2 
among the three proteins on the list (Table 2). The only other protein that was affinity 
captured from the cell lysates was the α-subunit of the proteasome. While it is not clear 
whether or not the β-lactone inhibits the actinobacterial proteasome, inhibition of this non-
essential enzyme could not explain the growth inhibitory effects of the β-lactones. These 
results provide strong evidence that the bioactivity of the β-lactones can be ascribed to 
inhibition of the essential ClpP peptidase in actinobacteria.
β-lactones Inhibit the Activity of M. tuberculosis ClpP in vitro
To determine if M. tuberculosis ClpP1P2 peptidase activity can be inhibited by β-lactones, 
we performed enzymatic assays in the presence and absence of the compounds. For these 
experiments, we cloned the clpP1 and clpP2 gene products from M. tuberculosis with C-
terminal His6 tags, over-expressed the proteins in a clpP null strain of Escherichia coli, and 
purified ClpP1 and ClpP2 by metal-affinity, anion-exchange, and size-exclusion 
chromatography (13,33,34). Formation and activation of the M. tuberculosis ClpP1P2 
complex has only been observed in vitro in the presence of short N-protected hydrophobic 
dipeptides, such as Z-Leu-Leu-CHO (18), which presumably serve as agonists by binding to 
the peptidase active sites. For our inhibition assays, we activated ClpP1P2 using a 
combination of Z-Leu-Leu-Nva-CHO (an N-protected tripeptide aldehyde, which activated 
to higher levels and at lower concentrations than dipeptides), E. coli ClpXΔN (which 
activated independently and in combination with agonists) and ATPγS (33). In the presence 
of ATPγS, ClpXΔN presumably enhances catalytic activity by binding to and stabilizing 
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catalytically active ClpP1P2 (33). The reactions were initiated by the addition of the 
fluorogenic tripeptide substrate, Z-Gly-Gly-Leu-AMC, and monitored by following the 
increase in fluorescence resulting from hydrolytic release of the aminomethylcoumarin 
(AMC) fluorophore.
β-lactones 4 and 7, which were most toxic to M. tuberculosis, displayed dose-dependent 
inhibition of ClpP1P2 peptidase activity (Figs. 2A, 2B), supporting the hypothesis that 
inhibition in vivo occurs via modification of this target. β-lactone 7, the most potent inhibitor 
identified in this study, is structurally distinct from previously reported β-lactone inhibitors 
of ClpP (20–23). It contains a benzylic substituent on the α-carbon, rather than an 
unbranched aliphatic chain, and an alkyl chain on the β-carbon. Interestingly, we note that 
significantly lower concentrations of β-lactones 4 and 7 were required to suppress 
mycobacterial growth than for inhibition of ClpP activity in vitro and that the inhibition was 
not quantitative. Sieber and co-workers reported similar observations wherein β-lactones 
that suppress virulence factor production in S. aureus in the nanomolar range only partially 
inhibit the ClpP peptidase in vitro in the micromolar range (20, 25). The differences in the 
observations in vivo and in vitro could be explained by the possibility that a modest degree 
of ClpP inhibition may be sufficient for suppression of mycobacterial growth. While we 
cannot rule out the possibility that the compounds have other essential targets, these 
observations could also be explained by the poor solubilities of the compounds in the 
enzymatic assays or by incomplete reconstitution of ClpP1P2 activity in vitro. Indeed, the 
reconstitution of a catalytically active tetradecamer of M. tuberculosis ClpP1P2 is not trivial 
and requires the inclusion of agonists (18) and/or a heterologous AAA+ partner. Although 
the mechanistic basis of the agonists is ill-defined (18), their requirement in assays in vitro 
suggests that an unidentified activator or regulatory partner may stimulate M. tuberculosis 
ClpP1P2 activity in vivo.
Following inhibition of ClpP1P2 with β-lactone 7 in vitro, we searched for sites of 
modification by mass spectrometry following digestion with trypsin and Asp-N. As 
evidenced by a 204 Dalton increase in the peptide masses, these experiments revealed β-
lactone modification of the active-site serine of ClpP2 (Fig. 2C). In contrast, we did not 
recover modified peptides from ClpP1 active site. Thus, under the conditions of these 
assays, β-lactone 7 selectively inhibits ClpP2. We found that β-lactone 4 also selectively 
inhibits ClpP2 (data not shown). Similar observations have recently been reported with the 
ClpP1P2 peptidase in L. moncytogenes (35). These results are consistent with the 
observation that the peptidase activities of ClpP1 and ClpP2 have somewhat different 
specificities (18,45). They also provide an explanation for the partial inhibition of ClpP 
peptidase activity shown in Figures 2A and 2B. Interestingly, both ClpP1 and ClpP2 in M. 
smegmatis and in S. coelicolor (Table 2) were captured in the aforementioned chemical 
proteomic experiments. Based on the in vitro analyses, it is likely that ClpP1 is affinity 
captured in vivo not by a reaction, but by its association with ClpP2. These results are 
noteworthy because they provide clear evidence that the β-lactones that suppress the growth 
of M. tuberculosis also inhibit its ClpP peptidase in vitro.
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An Auxiliary clpP Locus in Streptomyces coelicolor Confers Resistance to β-lactones
Mining the genomes of antibiotic-producing bacteria has proven to be a powerful strategy 
for the identification of antibacterial drug resistance genes (46–49). To identify putative 
determinants of resistance to β-lactone inhibitors of ClpP, we searched publicly available 
genome sequences of antibiotic-producing Streptomyces bacteria and found that S. 
coelicolor A3(2), S. avermitilis, and S. lividans possess a clpP3clpP4 locus that is 
paralogous to clpP1clpP2 (see, www.streptomyces.org.uk). Paralogous genes are often 
associated with antibiotic resistance (36, 38–42). We chose to study the role of the 
paralogous clpP genes in β-lactone resistance in S. coelicolor because it is the model 
organism of the genus and readily amenable to genetic manipulation. In S. coelicolor, the 
clpP1clpP2 locus is comprised by genes SCO2618 and SCO2619, while the clpP3P4 locus 
includes genes SCO7280 and SCO7281 (30). Further, the S. coelicolor clpP1 and clpP3 
gene products are 59% identical in sequence, whereas the products encoded by clpP2 and 
clpP4 share 56% identity. Consistent with our prediction about the role of the auxiliary clpP 
locus, we found that S. coelicolor grew in media supplemented with high concentrations of 
β-lactones 4 or 7, whereas S. griseus IFO13350, a strain lacking clpP3clpP4, did not grow 
(Table 3). These results suggested that the auxiliary clpP locus confers β-lactone resistance. 
To test this hypothesis more directly, we constructed clpP1clpP2 and clpP3clpP4 null 
strains of S. coelicolor and assayed their susceptibilities to β-lactones. In support of this 
model, the clpP3clpP4-null strain was killed by aliphatic β-lactones 3 and 4, whereas the 
clpP1clpP2-null strain was resistant (Fig. 3; Table 3). The clpP3clpP4-null strain, by 
contrast, was only slightly more susceptible to β-lactone 7 than the clpP1clpP2-null strain, 
suggesting that β-lactone 7 inhibits both ClpP1P2 and ClpP3P4, albeit to different degrees. 
Further evidence that the compounds preferentially inhibit ClpP1P2 was the observation that 
wild-type S. coelicolor exhibited delayed sporulation in a manner reminiscent of the 
clpP1clpP2-null strain when grown on media supplemented with inhibitory β-lactones (Fig. 
S1).
In S. lividans, the clpP3clpP4 locus is only highly transcribed in a clpP1clpP2-null strain 
(40,43) because ClpP1P2 continuously degrades PopR, a regulatory protein that activates 
clpP3clpP4 transcription (40,43). Based on this model, we hypothesized that β-lactones 
might induce clpP3clpP4 transcription in S. coelicolor by inhibiting ClpP1P2. To test this 
prediction, we used semi-quantitative RT-PCR to assay clpP3clpP4 transcripts in wild-type 
S. coelicolor treated with either β-lactone or a DMSO control and found that clpP3clpP4 
mRNA was only abundant after treatment with β-lactones 2,3,4,7 (Fig. 4A). In control 
experiments with the clpP1clpP2-null strain, we observed constitutive transcription of 
clpP3clpP4 (Fig. 4B), in a manner reminiscent of the analogous null strain of S. lividans (40, 
43). Using 5′-RACE, we determined that the transcriptional-start sites of the clpP3clpP4 
operon are located 80 and 82 base pairs upstream of the predicted translation start site. The 
positions of these start sites are similar to the one for clpP3clpP4 transcription in S. lividans 
and are close to an inverted-repeat sequence to which PopR is likely to bind. (43) Since the 
regulatory gene popR is divergently transcribed from clpP3clpP4 operon in S. coelicolor, S. 
lividans, and S. avermitilis, these genes may comprise a mobile, autoregulatory antibiotic-
resistance locus.
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We report that disubstituted β-lactones inhibit the growth of wild-type strains of M. 
tuberculosis and M. smegmatis. The inhibition of growth by these molecules is markedly 
different from reports that compounds with related structures are not toxic to, but suppress 
virulence of pathogenic bacteria like Staphylococcus aureus and Listeria monocytogenes. 
The simple explanation for species-specific responses to the compounds is that ClpP is 
essential for viability in mycobacteria and other actinomycetes, but is only required for 
virulence in S. aureus and L. monocytogenes. While we cannot rule out other mechanisms 
by which these compounds could inhibit the growth of actinomycetes, observations reported 
here indicate that the toxic effects of these molecules can be ascribed to inhibition of 
essential ClpP peptidase activity. Specifically, we show that the toxic β-lactones inhibit M. 
tuberculosis ClpP peptidase activity in vitro. Consistent with the inhibition of the 
peptidolytic activity was the observation of a covalent adduct at the ClpP2 active site serine 
residue in a β-lactone treated preparation of the M. tuberculosis ClpP1P2 via mass 
spectrometry. The selective inhibition of ClpP2 by these compounds and their suppression 
of growth are consistent with reports that both clpP2 and clpP1 are essential for the viability 
of M. tuberculosis (7,11). Further, ClpP1 and ClpP2 were the only essential proteins 
identified in lysates of both S. coelicolor and M. smegmatis in in vivo chemical proteomic 
experiments, wherein proteins that reacted with an alkyne-substituted β-lactone were 
captured via a click reaction and analyzed. Additional evidence for ClpP inhibition by β-
lactones is the observation that treatment of wild-type S. coelicolor with these compounds 
caused the same defect in morphological differentiation seen in the clpP1clpP2 null strain. 
The proposed mode of antibacterial activity by β-lactones is further validated by our 
findings that a S. coelicolor strain lacking one of the two paralogous clpP loci (i.e., 
clpP3clpP4) is susceptible to disubstituted β-lactones, whereas the wild-type strain is 
insensitive to these compounds. Collectively, these observations indicate that inhibition of 
essential ClpP peptidase activity by small molecules critically compromises bacterial 
growth.
Genome mining efforts led to the discovery that paralogous clpP genes mediate resistance to 
β-lactones. This finding is yet another example of a paralogous gene encoding an antibiotic 
resistance determinants (38–42). The connection of the auxiliary clpP3clpP4 locus in S. 
coelicolor with resistance to β-lactones is noteworthy because it has recently been associated 
with resistance to ADEP antibiotics that act by dysregulating ClpP (40). Accordingly, it is 
remarkable the peptidase encoded by clpP3clpP4 confers resistance to two distinct structural 
classes of antibiotics that affect ClpP activity by completely different mechanisms. 
Fortunately, the sensitivity of a S. coelicolor strain harboring only ClpP3P4 to benzyl-
substituted β-lactone 7 indicates that the apparent resistance of this ClpP isoform can be 
circumvented. However, our findings regarding clpP3clpP4 do take on special relevance 
because there is evidence for the transfer of antibiotic resistance genes from Streptomyces 
bacteria to mycobacteria (52). In any case, the absence of a clpP3clpP4 locus in M. 
tuberculosis bodes well for the use of β-lactones and ADEPs as antibacterial drugs.
In summary, we report that β-lactones are a new privileged structure for inhibiting growth of 
mycobacteria and define a mechanism by which related actinobacteria can resist the toxic 
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effects of these compounds. Our finding that the most potent β-lactone, which inhibits the 
growth of mycobacteria and both clpP null mutants of S. coelicolor, has a benzyl substituent 
on the α-carbon is novel and suggests that the potency of β-lactones can be enhanced by the 
inclusion of aromatic substituents at this carbon. Further investigations into this substituent 
effect as it relates to antibacterial activity and ClpP inhibition, as well as mechanistic studies 
of ClpP3P4, are underway in these laboratories. Collectively, our results lend further 
credence to predictions that ClpP and other intracellular proteases in bacteria are 
pharmacologically tractable drug targets (12, 29), like their human and viral counterparts. 
Continued research in this area will hasten the development of new chemical entities in the 
armamentarium used to treat tuberculosis and other bacterial infections.
METHODS
Strains, Media and Culture Conditions
The strains and plasmids used in this work are listed in Tables S1 and S2. E. coli strains 
DH5α and ET12567/pUZ8002 were grown in Luria-Bertani medium at 37 °C for routine 
subcloning, whereas E. coli strain BW25113/pIJ790 was grown at 30 °C to maintain 
selection of pIJ790 (50). Streptomyces strains were grown at 30 °C on mannitol soya flour 
medium (SFM), Difco nutrient agar medium (DNA), yeast extract-malt extract medium 
(YEME), or minimal liquid medium (NMMP) (37). For transcriptional analyses, S. 
coelicolor strains were grown in NMMP. M. smegmatis MC2155 was grown in Luria-
Bertani medium supplemented with 0.2% (vol/vol) glycerol at 37 °C. M. tuberculosis 
H37Rv was maintained in Middlebrook 7H9 broth supplemented with 0.2% (vol/vol) 
glycerol, 0.05% Tween 80, and 10% (vol/vol) oleic acid-albumin-dextrose-catalase. For E. 
coli strains, ampicillin, apramycin, chloramphenicol, hygromycin, and kanamycin were 
employed at 100, 50, 25, 80, and 50 μg/mL, respectively. Nalidixic acid was used at 20 
μg/mL for counter selections of E. coli in conjugations with S. coelicolor. For S. coelicolor, 
apramycin and hygromycin were used at 50 μg/mL.
Synthesis of β-lactones
With the exceptions of β-lactone 1 (purchased from Aldrich) and β-lactone 14 
(salinosporamide, a gift from Prof. B. Moore), β-lactones were chemically synthesized by 
published methods (31, 32). Detailed synthetic procedures are available in the supporting 
information. All reagents were purchased from Sigma-Aldrich or VWR. Column 
chromatography was performed using 60 Å (230–400 mesh ASTM) silica gel. NMR 
analyses were performed on a Bruker Advance Ultrashield Spectrometer (400 or 300 MHz).
MIC assays
S. coelicolor and S. griseus MIC assays were performed on Difco nutrient agar medium 
supplemented with specific β-lactones. Growth was assessed after incubation at 30 °C for 48 
h. The lowest drug concentration that inhibited ≥90% growth was considered to be the MIC. 
M. smegmatis MIC assays were performed on Difco nutrient agar medium supplemented 
with 0.2% glycerol and specific β-lactones. Growth was assessed after incubation at 30 °C 
for 72 h. The lowest drug concentration that inhibited ≥90% growth was considered to be 
the MIC. To determine the MICs of compounds for M. tuberculosis, the resazurin-based 
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microplate assay was performed. Briefly, β-lactones were resuspended in DMSO and tested 
in a range from 10 to 0.08 mg/L following a 2-fold dilution scheme. After addition of the 
bacterial cells at 105 cfu/mL, the 96-well plates were incubated at 37 °C for 5 days. 
Resazurin was added (0.05 mL of a 0.1% solution), and cultures were incubated for 2 
additional days at 37 °C. Fluorescence was measured using a Fluoroskan Ascent microplate 
fluorimeter (Thermo Scientific) with an excitation of 530 nm and emission of 590 nm. Wells 
containing only β-lactones were used to detect auto-fluorescence of compounds. The lowest 
drug concentration that inhibited ≥90% growth was considered to be the MIC. A 2-fold 
variation in MIC was considered to be within the error range of the assay. The final 
concentration of DMSO in all wells was 0.625%.
Affinity Capture of β-lactone Modified Proteins
Shaken liquid cultures (10 mL) of Streptomyces coelicolor M145 and Mycobacterium 
smegmatis MC2155 were grown to stationary phase and harvested by centrifugation at 4,000 
rpm for 10 min. The resulting bacterial cell pellets were washed twice with 5 mL of 
phosphate buffer saline (PBS) to remove secreted proteins, and resuspended in 500 μL PBS. 
The alkynyl β-lactone was added to a final concentration of 200 μg/mL and incubated at 
room temperature on a nutating mixer for 2 hours. (The β-lactone probe was applied from a 
20 mg/mL DMSO stock solution, such that DMSO concentration in the cell suspension did 
not exceed 1%.) Following incubation with the β-lactone probe, the cells were pelleted and 
washed three times with 1 mL PBS to remove excess probe. The cell suspensions were then 
lysed by treatment with lysozyme at a final concentration of 1 mg enzyme/mL of culture for 
45 min at 37°C and clarified. To remove proteins that bound non-specifically to the affinity 
matrix, 50 μL of a commercially available solution containing avidin-agarose beads (Sigma) 
were added to the lysates and the resulting solution was incubated at room temperature for 
30 minutes. After removal of the beads by centrifugation, 20 μM azido-PEG3-biotin (Alfa 
Aesar) and 1 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) were added to the 
lysates and they were gently mixed by brief vortexing. In turn, the click reaction 
(cycloaddition) was promoted by the addition of 1 mM CuSO4 catalyst and allowed to 
proceed for 1 hour at room temperature with gentle agitation. Once the CuSO4 was removed 
by centrifugation, the click reaction products were captured by incubation with 50 μL of the 
commercially available solution containing avidin-agarose beads for 1 hour. Control 
experiments in which the samples were not treated with either azido-biotin or with the 
Cu(II) catalyst were performed in parallel. To prepare for the protein-enriched beads for 
proteomic analysis, they were washed five times with 1 mL PBS and three times with 1 mL 
of a saturated NH4Cl solution.
Protein identification via mass spectrometry and bioinformatics
In all cases, the bead-bound proteins were tryptically digested and the resulting peptides 
were loaded onto a reverse phase column and separated by an Agilent 1200 HPLC. In 
addition to analysis of the experimental samples in this way, we also analyzed the protein-
enriched beads used to remove non-specifically binding proteins, as well as those from all of 
the aforementioned negative controls. The peptides were identified by tandem, high-
resolution MS/MS analyses using a coupled LTQ Orbitrap Velos Mass Spectrometer. The 
mass spectral data were searched using the MASCOT software algorithm against the 
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corresponding bacterial protein databases. In the bioinformatic identifications of the peptide 
fragments, trypsin specificity with two missed cleavage sites was allowed and the MS mass 
tolerance was 7 ppm while the MS-MS tolerance was 0.5 Daltons. Identifications were 
contingent on at least one unique peptide spectrum match (PSM) in the molecular weight 
search (MOWSE) with a protein score cut-off of 32.8. A complete list of the proteins that 
were identified can be found in the supporting information.
Plasmids and primers
Standard cloning procedures were employed to generate the plasmids listed in Table S2. 
Genes encoding mature M. tuberculosis ClpP1 and ClpP2 (spanning residues 7–200 and 13–
214, respectively (18) were amplified by PCR from M. tuberculosis H37Rv genomic DNA 
(ATCC) and cloned into the expression vector pET-22b (EMD) in frame with a C-terminal 
His6 tag. PCR was performed with Taq (Invitrogen) and Pfu (Stratagene, Agilent 
Technologies). All PCRs were performed with 5% (vol/vol) dimethylsulfoxide (DMSO).
Protein expression and purification
ClpP1 and ClpP2 were individually overexpressed in the clpP− E. coli strain JK10 (13) in 
LB broth at room temperature, following induction with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). Protein was purified from clarified lysates by metal affinity 
(HisPur Ni-NTA agarose, Thermo), anion exchange (MonoQ, GE Healthcare), and size-
exclusion chromatography (Superdex 200, GE Healthcare). Purified ClpP1 and ClpP2 were 
concentrated in Amicon centrifugal concentration devices (Millipore) to ≥80 μM 
tetradecamer in storage buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol).
E. coli ClpXΔN (residues 62–425), bearing an N-terminal His6 tag followed by a tobacco 
etch virus (TEV) protease cleavage site, was cloned into pET-21a (EMD) and overexpressed 
in ER2566 (NEB) E. coli. ClpXΔN was purified from clarified lysates by metal affinity 
chromatography. The His6 tag was removed by overnight incubation at 4 °C with TEV 
protease (1 μg TEV per 50 μg ClpXΔN) in 25 mM HEPES pH 8, 50 mM NaCl, 1 mM 
EDTA, and 1 mM DTT. ClpXΔN was further purified by anion exchange (MonoQ, GE 
Healthcare) and size-exclusion chromatography (Superdex 200, GE Healthcare), and was 
concentrated to 30 M hexamer in storage buffer.
Peptidase assays
Peptidase assays were carried out at 30 °C in 25 mM HEPES (pH 7.0), 100 mM KCl, 5 mM 
MgCl2, 0.5 mM EDTA, 1 mM tris(2-carboxyethyl)phosphine (TCEP), and 20% (vol/vol) 
DMSO. M. tuberculosis ClpP1P2 (0.5 μM tetradecamer), Z-Leu-Leu-Nva-CHO (50 μM; 
Enzo Life Sciences), E. coli ClpXΔN (1 μM hexamer), and adenosine 5'-(γ-thiotriphosphate) 
(1 mM ATPγS; EMD) were incubated with the inhibitor for 30 min. Reactions (40 μL) were 
initiated by the addition of Z-Gly-Gly-Leu-AMC substrate (Enzo Life Sciences) to a final 
concentration of 100 μM. Substrate cleavage was monitored in a SpectraMax M5 microplate 
reader (Molecular Devices) by exciting at 380 nm and following the increase in 460 nm 
fluorescence.
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ClpP1P2 (3 μM tetradecamer), Z-Leu-Leu-Nva-CHO (50 μM), ClpXΔN (2 μM hexamer) and 
ATP-γ-S (1.5 mM) were incubated with β-lactone 7 (200 μM) for 1 h at 30 °C, and buffer 
exchanged into 50 mM ammonium bicarbonate using a SpinOUT desalting column (G-
biosciences). Follow treatment with dithiothreitol, the protein was alkylated with 
iodoacetamide, and subjected to serial overnight digestion at 37 °C by trypsin (Sigma) and 
endopeptidase Asp-N (Sigma). LC-MS/MS analyses of the resulting peptides was performed 
on a LTQ Ion Trap mass spectrometer (Thermo Scientific) at the Koch Institute Proteomics 
Core Facility. Peptides were identified by the Mascot software package (Matrix Science) by 
searching against all possible peptides resulting from trypsin/Asp-N cleavage of bacterial 
protein sequences in the Swiss-Prot database. Data were visualized using the Scaffold 
software package (Proteome Software).
Construction of clpP1clpP2 and clpP3clpP4 null mutants
Using a published procedure for gene replacement in Streptomyces bacteria (50), strains of 
S. coelicolor were constructed in which either the clpP1clpP2 locus (SCO2618-19) or the 
clpP3clpP4 locus (SCO7280-81) was replaced with an apramycin (apr) resistance cassette. 
The loci replacements were confirmed by PCR analyses of genomic DNA from the null 
strains. In both, the null mutants' phenotypes were suppressed by complementation. Detailed 
procedures for the construction of the null strains are available in the supporting 
information.
Transcriptional Analyses
To analyze the transcription of the clpP operons, strains were grown for 21 hrs in NMMP 
media prior to treatment with 50 μg/ml of β-lactone or DMSO as a negative control. Cells 
were further incubated for 3 hrs. 1.5-mL culture aliquots were obtained and washed once 
with 10.3% (wt/vol) aqueous sucrose, followed by the addition of 100 μL of 10 mg/mL 
lysozyme solution (50 mM Tris-HCl, 1 mM EDTA, pH 8.0). The cells were incubated at 37 
°C for 15 min. Total RNA was isolated using the RNeasy Mini Kit (Qiagen) following the 
manufacturer's protocol. RNA concentrations were measured using a NanoDrop ND-1000 
spectrophotometer. An equal quantity of total RNA (1.0 μg) was employed in all reverse 
transcription-PCRs (RT-PCRs). RT-PCR was performed with the OneStep RT-PCR kit 
(Qiagen) according to the manufacturer's protocol for transcripts with high GC content. A 
215-bp complementary DNA (cDNA) corresponding to the clpP1clpP2 (SCO2618-19) 
transcript and a 314-bp cDNA corresponding to the clpP3clpP4 (SCO7280-81) transcript 
were detected with clpP1clpP2 RT-PCR primers and clpP3clpP4 RT-PCR primers, 
respectively. In a positive control experiment, a 486-bp cDNA corresponding to the hrdB 
gene (SCO5820) transcript, which encodes a vegetative sigma factor, was detected with 
hrdB RT-PCR primers. All primer sequences are listed in Table S3 in the supporting 
information. The PCR program used for the detection of all transcripts was 50 °C for 30 
min, 95 °C for 15 min, 30 cycles of 94 °C for 30 s, 57 °C for 30 s, and 72 °C for 60 s, and a 
final elongation at 72 °C for 10 min. No signals were detected in control experiments with 
Pfu polymerase, indicating that the RT-PCR signals correspond to the amplification of 
mRNA transcripts.
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The transcriptional start site of the clpP3p4 locus was identified using the 5′-RACE System 
for Rapid Amplification of cDNA Ends, Version 2.0 (Invitrogen), using the manufacturer's 
protocol for high GC-content transcripts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Evidence for in vitro inhibition of ClpP1P2 by β-lactones
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S. coelicolor null mutant susceptibly to β-lactones
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Transcriptional Analysis of clpP3clpP4
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Table 1
Minimal Inhibitory Concentrations of β-lactones for Mycobacteria
Compound
MIC (μg/mL)
M. smegmatis MC2115 M. tuberculosis H37Rv
2 250 Not tested
3 150 Not tested
4 45 47
7 10 28
β-lactone minimal inhibitory concentrations (MICs) for M. smegmatis and M. tuberculosis. MICs of representative antibacterial drugs against M. 
tuberculosis H37Rv are as follows: moxifloxacin - 8 μg/mL, isoniazid - 2 μg/mL, kanamycin - 1.2 μg/mL, streptomycin - 16 μg/mL, ethambutol - 4 
μg/mL (49).
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Table 2
Proteins identified in chemical proteomic analyses
Streptomyces coelicolor Mycobactehum smegmatis
Aconitate hydratase Beta-lactamase
Aminolevulinic acid dehydratase ClpB
ClpP1 ClpP1
ClpP2 ClpP2
DNA binding protein, EngD D-alanyl-D-alanine carboxylpeptidase
Molybdenum cofactor protein, MoaC Leucyl-tRNA synthetase
Proteasome α-subunit Malate dehydrogenase
Pyridoxal lyase, PdxS Purine biosynthesis protein, PurH
Proteasome β-subunit




Proteins identified in both S. coelicolor and M. smegmatis are shown in bold text. In the bioinformatic identifications of the peptide fragments, a 
trypsin specificity with two missed cleavage sites was allowed and the MS mass tolerance was 7 ppm while the MS-MS tolerance was 0.5 Daltons. 
Identifications were contingent on at least one unique peptide spectrum match (psm) in the molecular weight search (MOWSE) with a protein score 
cut-off of 32.8. An additional information on the proteins in this list can be formed in Tables S4and S5.
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Table 3
Minimal Inhibitory Concentrations of β-lactones for Streptomyces bacteria
Compound Strain MIC (μg/mL)
WT >800
Δ clpP 1/2::apr >800
Δ clpP 3/4::apr 600
S. griseus 650
WT >800
Δ clpP 1/2::apr >800
Δ clpP 3/4:: apr 550
S. griseus 580
WT >800
Δ clpP 1/2::apr 300
Δ clpP 3/4::apr 250
S. griseus 250
β-lactone minimal inhibitory concentrations (MICs) for wild-type S. coelicolor, S. coelicolor clpP1clpP2 and clpP3clpP4 null strains, and 
S.griseus. The β-lactones are partially insoluble at concentrations above 800 μg/mL.
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